Free Trial

Virpax Pharmaceuticals (VRPX) Competitors

Virpax Pharmaceuticals logo
$0.38 +0.03 (+8.94%)
As of 11:35 AM Eastern

VRPX vs. ONCT, SHPH, ADXS, BPTH, PTEIQ, ASLN, CWBR, EVFM, PBLA, and PTPI

Should you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Oncternal Therapeutics (ONCT), Shuttle Pharmaceuticals (SHPH), Ayala Pharmaceuticals (ADXS), Bio-Path (BPTH), PolarityTE (PTEIQ), ASLAN Pharmaceuticals (ASLN), CohBar (CWBR), Evofem Biosciences (EVFM), Panbela Therapeutics (PBLA), and Petros Pharmaceuticals (PTPI). These companies are all part of the "pharmaceutical products" industry.

Virpax Pharmaceuticals vs. Its Competitors

Virpax Pharmaceuticals (NASDAQ:VRPX) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Virpax Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Virpax Pharmaceuticals currently has a consensus target price of $75.00, indicating a potential upside of 19,636.84%. Oncternal Therapeutics has a consensus target price of $10.00, indicating a potential upside of 1,798.97%. Given Virpax Pharmaceuticals' higher probable upside, analysts clearly believe Virpax Pharmaceuticals is more favorable than Oncternal Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virpax Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Oncternal Therapeutics
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25

Virpax Pharmaceuticals has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -1,599.95%. Oncternal Therapeutics' return on equity of -177.58% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Oncternal Therapeutics -1,599.95%-177.58%-131.30%

Virpax Pharmaceuticals has higher earnings, but lower revenue than Oncternal Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19MN/AN/A
Oncternal Therapeutics$790K1.97-$39.48M-$11.69-0.05

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.0% of Oncternal Therapeutics shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 11.2% of Oncternal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Oncternal Therapeutics had 1 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 1 mentions for Oncternal Therapeutics and 0 mentions for Virpax Pharmaceuticals. Virpax Pharmaceuticals' average media sentiment score of 0.00 beat Oncternal Therapeutics' score of -0.26 indicating that Virpax Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Oncternal Therapeutics Neutral

Summary

Oncternal Therapeutics beats Virpax Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Virpax Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRPX vs. The Competition

MetricVirpax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$472K$768.81M$5.51B$8.92B
Dividend YieldN/A4.84%5.38%4.12%
P/E RatioN/A1.2726.2119.84
Price / SalesN/A219.23415.30113.63
Price / CashN/A23.4436.4957.06
Price / Book0.235.918.005.32
Net Income-$15.19M-$27.56M$3.15B$248.42M
7 Day Performance14.53%-0.39%1.72%2.50%
1 Month Performance55.10%6.71%4.63%5.53%
1 Year Performance-97.14%9.48%35.87%19.65%

Virpax Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRPX
Virpax Pharmaceuticals
1.3506 of 5 stars
$0.38
+8.9%
$75.00
+19,636.8%
-97.2%$472KN/A0.007
ONCT
Oncternal Therapeutics
1.6178 of 5 stars
$0.53
flat
$10.00
+1,799.0%
N/A$1.56M$790K-0.0530News Coverage
SHPH
Shuttle Pharmaceuticals
0.8074 of 5 stars
$3.77
+9.9%
N/AN/A$1.51MN/A-0.915High Trading Volume
ADXS
Ayala Pharmaceuticals
N/A$0.03
+22.9%
N/A-87.0%$1.42M$3.24M0.0020Gap Up
BPTH
Bio-Path
2.4923 of 5 stars
$0.17
-3.4%
$20.00
+11,664.7%
-91.0%$1.41MN/A0.0010
PTEIQ
PolarityTE
N/AN/AN/AN/A$1.24M$810K-0.0560Gap Up
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat
N/AN/A$1.23M$12M-0.0330
CWBR
CohBar
N/A$0.41
flat
N/AN/A$1.19MN/A0.0010
EVFM
Evofem Biosciences
0.5453 of 5 stars
$0.01
+4.3%
N/A+10.0%$1.16M$11.39M-0.02120Gap Down
PBLA
Panbela Therapeutics
0.0863 of 5 stars
$0.23
+10.4%
N/A-47.3%$1.13MN/A0.006
PTPI
Petros Pharmaceuticals
1.1546 of 5 stars
$0.03
-5.4%
N/A-99.7%$1.04M$5.11M-0.0120Gap Down

Related Companies and Tools


This page (NASDAQ:VRPX) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners